Paper Details

  1. Home
  2. Paper Details

Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy.

Author: BottLaura C, ChenKe-lian, FischbeckKenneth H, HarmisonGeorge G, KatsunoMasahisa, PennutoMaria, RinaldiCarlo, SobueGen

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.

Overview

This study investigates the use of recombinant human IGF-1 in a mouse model of spinal and bulbar muscular atrophy, a motor neuron disease. The results show that IGF-1 treatment improves motor performance, reduces weight loss, and increases survival, suggesting its potential as a treatment for this disease.
Paper Details　
Original Abstract of the Article :
Spinal and bulbar muscular atrophy is an X-linked motor neuron disease caused by polyglutamine expansion in the androgen receptor. Patients develop slowly progressive proximal muscle weakness, muscle atrophy and fasciculations. Affected individuals often show gynecomastia, testicular atrophy and red...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521783/

データ提供：米国国立医学図書館（NLM）

The Potential of IGF-1 in Treating Spinal and Bulbar Muscular Atrophy

This study delves into the exciting world of [spinal and bulbar muscular atrophy (SBMA)] research, exploring the potential of [insulin-like growth factor 1 (IGF-1)] as a therapeutic agent. The researchers utilized a [transgenic mouse model] to investigate the effects of [IGF-1] on the progression of [SBMA]. They observed that [IGF-1] treatment resulted in [increased Akt phosphorylation and reduced mutant androgen receptor aggregation in muscle]. This led to [improved motor performance, attenuated weight loss and increased survival] in the treated mice.

Promising Insights into SBMA Treatment

These findings offer hope for individuals battling [SBMA]. The researchers' discovery that [IGF-1] can positively impact [SBMA] symptoms in mice opens the door for further investigation of its efficacy in human clinical trials. This could lead to the development of a much-needed disease-modifying therapy for [SBMA].

A Ray of Hope for Muscle Degeneration

These findings suggest that [IGF-1] could potentially be a key player in mitigating muscle degeneration associated with [SBMA]. While more research is needed, the prospect of [IGF-1] as a therapeutic agent provides a beacon of hope for individuals affected by this debilitating condition.

Dr.Camel's Conclusion

This study showcases the boundless potential of [IGF-1] in treating [SBMA]. Just like a camel traversing a vast desert, this research ventures into the unknown, seeking solutions for those struggling with [SBMA]. The results are encouraging, suggesting a potential path towards a better future for individuals with [SBMA].

Date :
  1. Date Completed 2013-05-09
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

22952056

DOI: Digital Object Identifier

PMC3521783

Related Literature

Article Analysis
・Effects of mecasermin injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.